Drug intelligence / Profile preview

SB000-AAV

Development stage: Preclinical
Lead developer: Shift Bioscience
Modality: Gene Therapies

Overview

SB000-AAV is an adeno-associated virus (AAV) gene therapy candidate being developed by Shift Bioscience for the treatment of age-related hearing loss. The therapy is designed to address the biological drivers of cellular aging within the auditory system by delivering a genetic payload via an AAV vector. As of early 2026, the program is in the preclinical stage of development, specifically undergoing in vivo proof-of-concept (POC) testing. The specific molecular target or transgene utilized in this therapy has not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SB000-AAV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB000-AAV.

Explore the full profile